CURR Insider Trading Activity and SEC Form 4 Filings
CURR insider trading summary
No open-market insider purchases or sales of Cure Pharmaceutical Holding Corp. (CURR) have been reported on SEC Form 4 in the past 12 months.
Latest CURR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 27, 2021 | Jonathan Berlent | Chief Business Officer | Buy | $7K (10,000 @ $0.69) |
| May 25, 2021 | Nancy Duitch | Chief Strategy Officer | Buy | $700 (1,000 @ $0.70) |
| May 24, 2021 | Robert Steven Davidson | Chief Executive Officer | Buy | $4K (6,443 @ $0.69) |
| May 21, 2021 | Nancy Duitch | Chief Strategy Officer | Buy | $4K (5,000 @ $0.73) |
| May 21, 2021 | Robert Steven Davidson | Chief Executive Officer | Buy | $5K (7,400 @ $0.71) |
| Dec 18, 2020 | Robert Steven Davidson | Chief Executive Officer | Buy | $3K (2,172 @ $1.44) |
| Dec 18, 2020 | Robert Steven Davidson | Chief Executive Officer | Buy | $3K (2,300 @ $1.42) |
| Dec 18, 2020 | Robert Steven Davidson | Chief Executive Officer | Buy | $4K (2,415 @ $1.45) |
| Mar 27, 2019 | Climate Change Investigation, Innovation & Investment Company, LLC | Insider | Sell | $26K (7,292 @ $3.60) |
| Mar 27, 2019 | Climate Change Investigation, Innovation & Investment Company, LLC | Insider | Sell | $1K (400 @ $3.65) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.